Key Highlights

• According to Telix's disclosures, the upfront consideration is US$1.65 billion on a cash-free, debt-free basis.

• About US$1.25 billion of that is to be paid in Telix shares, issued to ITM holders as American depositary receipts.

• A further amount of up to US$700 million is contingent on regulatory and sales milestones for ITM-11, ITM's lead radioligand therapy candidate.

• Telix reported group Revenue of US$245 million for the third quarter of 2026, up 19% on US$206 million a year earlier and down 1% on the second quarter.

What does a US$1.65 billion deal for ITM mean for Telix Pharmaceuticals (ASX:TLX), and can the company deliver it while its core imaging Business keeps growing? The proposed merger, announced on 21 September 2026, would pair Telix's commercial imaging Franchise with a radioisotope and therapeutics group. Its completion depends on a Shareholder vote that the company has flagged for 1 December 2026 (AEDT).

What the ITM transaction involves

According to Telix's disclosures, the upfront consideration is US$1.65 billion on a cash-free, debt-free basis. About US$1.25 billion of that is to be paid in Telix shares, issued to ITM holders as American depositary receipts. A further amount of up to US$700 million is contingent on regulatory and sales milestones for ITM-11, ITM's lead radioligand therapy candidate.

The deal is subject to shareholder approval, so it remains a proposal rather than a completed acquisition. If it proceeds, it would add isotope Supply and Manufacturing capability, a theme that matters in a sector where reliable supply of radioactive material is a recurring constraint. It would also add clinical-stage therapeutic Assets and bring integration work.

What Telix does and where revenue comes from

Telix develops and sells radiopharmaceuticals, which are medicines that carry a radioactive isotope to target disease. The company works in two broad ways. Diagnostic products use imaging to locate cancer, while therapeutic candidates aim to deliver radiation directly to tumour cells.

Revenue is dominated by its Precision Medicine segment, which the company says comes primarily from Illuccix and Gozellix, two PSMA-PET imaging products used in prostate cancer.

Third-quarter 2026 performance

Telix reported group revenue of US$245 million for the third quarter of 2026, up 19% on US$206 million a year earlier and down 1% on the second quarter. Precision Medicine contributed US$201 million, up 30% year on year, while TMS revenue was US$44 million, down 6%.

US dose volumes for Gozellix and Illuccix rose 1% on the previous quarter, suggesting growth has moderated sequentially. Management expects Precision Medicine revenue growth above 25% for 2026.

For the full year, guidance is revenue of US$950 million to US$970 million, with the company saying it is tracking towards the upper end. It expects other income of about US$40 million, which would take total revenue and other income above US$1 billion. Research and Development spending guidance has been narrowed to US$240 million to US$260 million, from US$230 million to US$270 million.

Pipeline and regulatory milestones

The FDA approved Pixclara (floretyrosine F 18) for glioma imaging on 14 September 2026, and first commercial doses were administered the same month. A Phase 3 study aimed at extending the label to brain metastases is progressing.

Zircaix, the kidney cancer imaging candidate, received a Complete Response Letter from the FDA. Telix says it has addressed the issue but is finalising a Biologics licence application resubmission to resolve remaining manufacturing observations, with resubmission planned in the near term. The timing of any eventual decision is outside the company's control.

Other programmes include:

• BiPASS, a Phase 3 trial of a PSMA imaging agent before prostate biopsy, completed enrolment of 350 patients, and the FDA has granted Fast Track designation.

• The OPTIMAL-PSMA therapy trial has enrolled 120 patients, with data expected in the first half of 2027.

• IPAX-2, a glioblastoma therapy study, met its primary endpoint of establishing a maximum tolerated dose, with no dose-limiting toxicities reported.

• A European Marketing authorisation application for Pixlumi remains under review, while in Japan a conditional approval for Illuccix is under review by the regulator, the PMDA, and a new drug application is being prepared.

These are clinical and regulatory steps, and none guarantees approval or commercial success.

Sector conditions and competitive position

Radiopharmaceuticals have drawn rising industry attention, with large pharmaceutical groups and specialist developers competing for isotope supply, manufacturing capacity and clinical talent. In PSMA-PET imaging for prostate cancer, Telix competes with other approved agents, so pricing, reimbursement and physician preference all influence volumes. The flat sequential dose growth reported in the third quarter is a data point investors may watch in that context.

Telix's advantages include an established US commercial footprint, a broadening product list and a pipeline that spans diagnostics and therapy. The ITM transaction is intended to strengthen the supply and therapeutic side of that model, although the benefits would depend on execution.

On governance, David Gill was appointed Board Chair on 1 September 2026. The company also announced an astatine-211 collaboration with Ekalia on 19 October 2026, extending its interest in alpha-emitting isotopes, though no financial terms were considered here.

Risks and what to watch

Several uncertainties stand out.

• The shareholder vote and any other conditions for the ITM transaction, expected around 1 December 2026.

• Integration risk, including combining manufacturing, supply and clinical operations across two companies.

• Concentration, because a large share of revenue comes from two prostate imaging products.

• Regulatory outcomes, including the Zircaix resubmission and the European Pixlumi review.

• Clinical risk in therapy trials, where results can fall short of earlier signals.

• Research spending, which remains substantial at US$240 million to US$260 million for 2026 guidance.

Upcoming reference points include the shareholder meeting, the Zircaix resubmission, further Pixclara uptake data, the OPTIMAL-PSMA readout in the first half of 2027 and the company's full-year result, which should show how the guidance ranges translate into reported figures.